Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Depreciation and Depletion (2017 - 2025)

Historic Depreciation and Depletion for Ascendis Pharma A (ASND) over the last 9 years, with Q4 2025 value amounting to $5.5 million.

  • Ascendis Pharma A's Depreciation and Depletion rose 1742.03% to $5.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.4 million, marking a year-over-year increase of 401.0%. This contributed to the annual value of $19.4 million for FY2025, which is 550.45% up from last year.
  • Per Ascendis Pharma A's latest filing, its Depreciation and Depletion stood at $5.5 million for Q4 2025, which was up 1742.03% from $4.6 million recorded in Q3 2025.
  • Ascendis Pharma A's Depreciation and Depletion's 5-year high stood at $5.5 million during Q4 2025, with a 5-year trough of $4.2 million in Q2 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $4.7 million (2024), whereas its average is $4.7 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 9753.5% in 2021, then crashed by 1037.36% in 2024.
  • Ascendis Pharma A's Depreciation and Depletion (Quarter) stood at $4.8 million in 2021, then decreased by 3.02% to $4.6 million in 2022, then increased by 12.47% to $5.2 million in 2023, then dropped by 10.37% to $4.7 million in 2024, then rose by 17.42% to $5.5 million in 2025.
  • Its Depreciation and Depletion stands at $5.5 million for Q4 2025, versus $4.6 million for Q3 2025 and $4.7 million for Q2 2025.